GEN Exclusives

More »

GEN News Highlights

More »
May 26, 2011

Pfizer Selects Parexel and Icon to Implement and Manage Clinical Trials

  • Pfizer has selected Boston-based Parexel, and Dublin, Ireland-based Icon, as its two preferred CROs for the provision of clinical development and trials services. The partnership agreements will be phased in over an 18–24-month period and will initially run for five years. Pfizer says the deals are in line with its remodeled R&D strategy, which involves partnering with third parties for services such as the implementation of clinical development programs. This will enable Pfizer to focus internally on its core strength in clinical trials design.

    “This new strategic partnership model is part of a comprehensive program to sharpen our research focus at Pfizer and creates a more flexible cost-base,” comments John Hubbard, svp for worldwide development at Pfizer.

    Under terms of the agreements, Pfizer will retain scientific ownership of clinical development processes and retain an overseeing role. Its new partners will provide their respective expertise in carrying out and managing global clinical trials, evaluating trail sites and countries, and optimizing and implementing data management, as well as reporting setup, fronting scientific and medical communications, and maintaining quality assurance.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »